Health Care • Medicinal Chemicals and Botanical Products
$6.09 ▲ +0.10
(+1.67%)
MKT CAP: $366.0M • VOL: 274.6K
52W L $3 52W H $7
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$5
MEDIAN
$7
MEAN
$7
HIGH
$8
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE OBIO TAPE
OBIO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $7.37 | $7.00 | 2025-02-14 | $5.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $7.67 | $7.19 | 2025-02-06 | $5.72 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $6.94 | $6.70 | 2025-01-29 | $5.85 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $6.21 | — | 2025-01-17 | $5.97 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $5.36 | $5.79 | 2025-01-09 | $5.42 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $7.25 | $6.33 | 2024-12-18 | $5.30 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $5.91 | $6.15 | 2024-12-04 | $5.66 | -4.3% | 48% | C |